Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-05
1999-09-28
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514423, 514883, A61K 3140
Patent
active
059589663
ABSTRACT:
Biomodulators, which regulate cellular differentiation and proliferation, as well as methods of use thereof, e.g., for treating various conditions, e.g., cancer, senescence, immunological disorders and vascular disease; for stimulating normal tissue architecture after injury; for vaccination; for stimulating the production of biologically important molecules by cells or organs in culture; for maintaining organs or tissues outside of a body after removal from the body and prior to transplantation; and for producing of vascular grafts for transplantation; are provided.
REFERENCES:
patent: 3983140 (1976-09-01), Endo et al.
patent: 4137322 (1979-01-01), Endo et al.
patent: 4198425 (1980-04-01), Mistui et al.
patent: 4248889 (1981-02-01), Oka et al.
patent: 4255444 (1981-03-01), Oka et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4681893 (1987-07-01), Roth
patent: 4710513 (1987-12-01), Willard et al.
patent: 4739073 (1988-04-01), Kathawala
patent: 4751235 (1988-06-01), Anderson
patent: 4755606 (1988-07-01), Wareing
patent: 4761419 (1988-08-01), Picard et al.
patent: 4808607 (1989-02-01), Wareing
patent: 5588715 (1996-12-01), Damon, II
Rice, F.A.H., "Isolation from Penicillium gilmanii of a Substance the Causes Leucocytosis in Rabbits", pp. 189-192 (1980.
Rice et al, "Chemical Determination of Leucogenenol and Its Production by Penicillium gilmanii", Applied Microbiology 15:790-793 (1967).
Rice, F.A.H., "The Structure of Leucogenenol", J. Chem. Soc. (C), pp. 2599-2605 (1971).
Hayflick, Leonard, Ann. Rev. Gerontol Gerrat 1:26-67 (1980).
Schneider et al, "Skin fibroblast cultures derived from members of the Baltimore Longitudinal Study: a new resource for studies of cellular aging", Cytogenet. Cell Genet. 31:40-46 (1981).
Martin et al, "Replicative Life-Span of Cultivated Human C", Laboratory Investigation 93(1),86-(1970).
Goldstein, Samuel, "Replicative Senescence: The Human Fibroblast Comes of Age", Science 249:119 (1990).
Cristofalo et al, "Molecular Biology of Aging", Surgical Clinics of North America 74(1):1-21 (1994).
Rice, Frederick A.H., "Isolation from Penicillium gilmanii of a substance that causes leucocytosis in rabbits", Proc. Soc. Exp. Biol. Med. 123(1):189-192 (1966) No. 38743.
Stoessl et al, "Colletruncoic Acid Methyl Ester, a Unique Meroterpenoid from Colletotrichum truncatum", Z. Naturforsch. 41c:677-680 (1986).
Dennis et al, "Growth Inhibition of Human Melanoma Tumor Xenografts in Athymic Nude Mice by Swainsonine", Cancer REsearch 50:1867-1872 (1990).
Mohla et al., "Inhibition of Growth of Subcutaneous Xenografts and Metastasis of Human Breast Carcinoma by Swainsonine: Modulation of Tumor Cell HLA Class I Antigens and Host Immune Effector Mechanisms", Anticancer Research 10:1515-1522 (1990).
Dennis, Effects of Swainsonine and Polyinosinic: Polycytidylic Acid on Murine Tumor Cell Growth and Metastasis:, Cancer Research 46:5131-5136 (1986).
Bowlin et al, "Potentiation of Human Lymphokine-activated Killer Cell Activity by Swainsonine, an Inhibitor of Glycoprotein Processing", Cancer Research 49:4109-4113 (1989).
Myc et al, "Effect of Swainsonine on Stimulation and Cell Cycle Progression of Human Lymphocytes", Cancer Research 49:2879-2883 (1989).
Waxdal, "Isolation, Characterization, and Biological Activities of Five Mitogens from Pokeweed", Biochemistry 13(18):-3671-3677 (1974).
Mann et al, "Cell Surface Oligosaccharide Modulation During Differentiation: V. Partial Characterization of the Regulated Surface During Substrate Adhesion and Spreading", Mechanisms of Ageing and Development 62:47-77 (1992).
Kino et al, "Studies of an Immunomodularor, Swainsonine: II. Effect of Swainsonine on Mouse Immunodeficient System and Experimental Murine Tumor", The Journal of Antibiotics 38:936-940 (1985).
Humphries et al., "Augmentation of Murine Natural Killer Cell Activity by Swainsonine, a New Antimetastatic: Immunomodulator", Cancer Research 48: 1410-1415 (1988).
Mann et al., "Biomodulation: An integrated approach to access and manipulate biological information", In: Gabius HJ, Gabius S., eds. Lectins and Cancer, Berlin Heidelberg: Springer-Verlag; 179-206 (1991).
Bitner et al, "Enhanced Tumor Imaging with Pokeweed Mitogen", Nucl. Med, Biol. 20(2):203-210 (1993).
Mann, "Biomodulation: an alternate approach to disease management", Curr. Opin. Invest, Drugs 2(9):1007-1014 (1993).
Mann et al, "Cell Surface Oligosaccharide Modulation During Differentiation: VI. The Effect of Biomodulation on the Senescent and Neoplastic Cell Phenotype", Mechanisms of Ageing and Development 62:79-110 (1992).
Mann Paul L.
Mash Eugene
Scallen Terence J.
University of New Mexico
Weddington Kevin E.
LandOfFree
Treatment of aberrant cellular states with biomodulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of aberrant cellular states with biomodulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of aberrant cellular states with biomodulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-703871